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In Japan, sorafenib and sunitinib, potential molecular targeted agents for advanced renal cell carcinoma,
were approved in 2008. Currently, a total of four agents, including everolimus and temsirolimus in addition
to these two agents, have been introduced into clinical practice. It would be comparatively easy to
determine the indication of these molecular targeted agents because of several clinical guidelines developed
based on the outcomes of reliable randomized clinical trials ; however, any adverse events associated with the
use of these agents, need to be managed carefully according to each case. Furthermore, it seems difﬁcult to
properly manage adverse events encountered during treatment using these agents due to the following
reasons : there are several adverse events which have not been experienced by urologists before, and there are
marked differences in the incidence as well as severity of adverse events associated with these agents between
the Western and Japanese populations. It is particularly important to try to achieve a maximal therapeutic
beneﬁt from treatment with molecular targeted agents through optimal management for adverse events
associated with these agents. In this symposium, accordingly, ﬁve experts, well informed of the use of these
agents, provided practical information on the management of adverse events associated with each agent.
(Hinyokika Kiyo 58 : 633, 2012)
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